Curapath Strengthens Partnership in Breakthrough Genetic Medicine with Multiyear Development and Manufacturing Agreement

February 15, 2024 12:00 AM AEDT | By EIN Presswire

Google News:

Curapath Strengthens Partnership in Breakthrough Genetic Medicine with Multiyear Development and Manufacturing Agreement — Image source: EIN Presswire

Recent News

Mount Burgess (ASX: MTB) Secures Financial Backing Through Strategic S...

Brighter Signals Emerges from Stealth

Monumental Energy Announces Completion of Workover and Resumption of C...

Stellantis N.V. Leadership Restructure Drives Strategic Alignment – FT...

VALENCIA, SPAIN, February 14, 2024 /EINPresswire.com/ -- Curapath, a leader in the development and custom manufacturing of polymer- and lipid-based delivery systems for advanced therapies, has entered into a multiyear Development and Manufacturing Services Agreement with a key customer located in North America. Under this agreement, Curapath will leverage its expertise in Novel Functional Excipients to complete process characterization, process performance qualification (PPQ), and other necessary studies. Anticipated to progress to commercial stages at Curapath Manufacturing site in Valencia in 2025, this multi-year agreement holds the potential to represent a double-digit million revenue contract for Curapath, subject to successful PPQ campaigns and regulatory approvals. This marks a significant milestone in the partnership between the two companies, with Curapath supporting the project since its early development stages.

“We are tremendously grateful for the trust placed in our team over the past few years” said Vicent J. Nebot, Chief Technical Officer of Curapath. “Being part of this pivotal moment and contributing to the delivery of this new disruptive therapy to patients is both an honor and a driving force to continue delivering our best to the advancement of our customer´s innovative therapies."

“Our team's dedication to advancing innovative therapies is unwavering. Building upon this relationship, we take pride in supporting our customer´s project and are fully committed to expand and adapt our manufacturing capacities and capabilities to fast evolving needs of advanced therapies." Said Philippe Clavel, Chief Executive Officer of Curapath.

About Curapath

Curapath, with over a decade of unwavering commitment, is dedicated to transforming lives through innovative therapies. With strong expertise in the development and manufacturing of polymers, lipid excipients, and optimized nanoparticle formulations, Curapath simplifies your non-viral gene therapy manufacturing process, offering seamless scalability for both small and large-scale cGMP manufacturing volumes. Having supported more than 50 therapeutic programs in advanced drug delivery formulations through the clinical journey to commercialization, Curapath is the proven CDMO partner to choose for unleashing innovative therapies and confidently navigating the journey from concept to impact on patients. For more information, please visit www.curapath.com.

Amador García
Curapath
[email protected]
Visit us on social media:
LinkedIn

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.